NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/03/2026
Voltar para busca
Dado oficial do USPTO
CANCERVISION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CANCERVISION
ST13
US500000097414523Classe
42, 44
Pedido
97414523
Registro
8196483
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
31/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 44
Data de depósito
17/05/2022
Data de registro
31/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/03/2026
Última transação
31/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
22/03/2024
Primeiro uso no comércio
22/03/2024
Código do desenho
4
Tipo de titular
03
Localização do titular
SAN DIEGO, CA, US
Examinador
GOODWIN, KATRINA JOYE
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
INOCRAS INC.
GENOME INSIGHT, INC.
Representantes
Miriam D. Trudell Davis Graham & Stubbs LLC
Classificação técnica
Classes Nice
Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Consultancy relating to research in the field of pharmacogenetics; scientific laboratory services namelysolvent testing services; scientific research in the field of genetic engineering; laboratory research in the field of gene expression; scientific research namelyresearch in the field of gene analysis; genetic testing for scientific research purposes namelygenetic fingerprinting; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics; scientific research namelygenetic research; genetic testing for scientific research purposes; scientific research; web site design; creating and designing website-based indexes of information for others using information technology; product research namelyresearch into new products; provision of internet search engines; database development services; developmentprogrammingimplementation of software for others; scientific research namelyresearch and testing services in the fields of bacteriology and virology; remote monitoring of medical data for medical diagnosis namelytechnical and scientific monitoring services relating to medical diagnostic instruments; structural and functional analysis of genomes
Classe 44
Medical and pharmaceutical consultation namelyconsultancy and information services relating to biopharmaceutical products; medical services namelymedical and health services relating to DNAgenetics and genetic testing; genetic testing for medical purposes; medical services namelyprovision of genetic information for medical treatment purposes; Genetic testing of animals for diagnostic or treatment purposes; psychological consultation; beauty consultation services in the selection and use of cosmetics; consultancy services relating to beauty; providing information about beauty; health spa services namelycosmetic body care services; pharmaceutical advice; medical services namelyanalysis of human biodata for medical purposes; medical services namelyprovision of genetic testing for medical treatment purposes; medical services namelyprovision of gene therapy for medical treatment purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/03/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/03/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/03/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
09/03/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/03/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
09/03/2026
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
09/03/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
23/12/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/12/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/09/2025
IUAF
USE AMENDMENT FILED
23/06/2025
EISU
TEAS STATEMENT OF USE RECEIVED
23/06/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
20/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/03/2025
PUBO
PUBLISHED FOR OPPOSITION
25/03/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/03/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/03/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
03/03/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/03/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
03/03/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/03/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/11/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/11/2024
GNRT
NON-FINAL ACTION E-MAILED
14/11/2024
CNRT
NON-FINAL ACTION WRITTEN
14/11/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
16/02/2024
DOCK
ASSIGNED TO EXAMINER
15/02/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
05/01/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/05/2023
GNSL
LETTER OF SUSPENSION E-MAILED
11/05/2023
CNSL
SUSPENSION LETTER WRITTEN
11/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
13/03/2023
GNRT
NON-FINAL ACTION E-MAILED
13/03/2023
CNRT
NON-FINAL ACTION WRITTEN
13/03/2023
DOCK
ASSIGNED TO EXAMINER
06/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/05/2022
NWAP
NEW APPLICATION ENTERED
20/05/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CANCERVISION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.